Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Breakthrough Device Designation

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Feb 05, 2024 4:12pm

243 Views

Post# 35863923

RE:RE:Breakthrough Device Designation

It's starting to feel like Sept. 2016 around here with all the positivity and expectation of success. But this time around it looks like it's really going to happen. I hope a lot of longs are still around for a long delayed redemption.

ChesterLives wrote: Great read for all the newbies to Spectral. There is an ironclad foundation to this trial and this is worth a re read or especially a read for the first time.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China